计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
MI-503 MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations.
Targets
Menin-MLL interaction (Cell-free assay) 14.7 nM
In vitro
Treatment of murine bone marrow cells (BMC) transformed with the MLL-AF9 oncogene with MI-503 results in substantial growth inhibition, with half-maximal growth inhibitory concentration (GI50) values of 0.22 μM, measured after 7 days of treatment. The cell growth inhibitory effect of MI-503 is time-dependent, with a pronounced effect achieved after 7-10 days of treatment. MI-503 is also very effective in inducing differentiation of MLL leukemia cells and substantially increases expression of CD11b, a myeloid differentiation marker. These effects are accompanied by reduced c-kit (CD117) expression, a marker associated with leukemia stem cells (LSCs). Treatment with sub-micromolar concentrations of MI-503 also leads to markedly reduced expression of Hoxa9 and Meis1, downstream targets of MLL fusion proteins substantially upregulated in MLL leukemias.
In vivo
MI-503 has very favorable drug-like properties, including metabolic stability and pharmacokinetic profile in mice. It blocks hematologic tumors in vivo and reduces MLL leukemia tumor burden. MI-503 achieves high level in peripheral blood following a single intravenous or oral dose, while also showing high oral bioavailability (~75%). Prolonged treatment (38 days) with MI-503 induces no toxicity in mice as reflected by no alterations in the body weight and no morphological changes in liver and kidney tissues. MI-503 could substantially improve survival of MLL leukemic mice and does not impair normal hematopoiesis in vivo.
Cell Research(from reference)
Cell lines:MV4;11 human leukemia cells expressing MLL-AF4
Incubation Time:7days
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 吲哚及其衍生物 |
| 亚类(Subclass) | N-烷基吲哚 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | N-烷基吲哚 |
| 其他上位类(Alternative Parents) | 噻吩并嘧啶类 吲哚 2,3,5-三取代噻吩 氨基嘧啶及其衍生物 芳烷基胺 取代吡咯 苯类化合物 咪唑内酰胺类 哌啶类 杂芳族化合物 吡唑类 三烷基胺 氮杂环化合物 腈类 碳氢化合物衍生物 烷基氟化物 有机氟化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 2,3,5-三取代噻吩 - 氟化烷基 - 烷基溴化物 - 氨基酸 - 氨基吡啶 - 芳烷基胺 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 苯基化合物 - 碳腈 - 氰化物 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 吲哚 - N-烷基吲哚 - 氰基化合物 - 有机硝基化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 哌嗪 - 吡唑 - 嘧啶 - 吡咯 - 取代吡咯 - 三元脂肪胺 - 三芳基胺 - 噻吩吡啶 - 噻吩 |
| 描述(Description) | 该化合物属于有机化合物中的正烷基吲哚类。这类化合物含有吲哚结构单元,其1位连接烷基链。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 | |
| 分析证书 | M413842 |